Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer

Paul A. DiSilvestro, MD, director, the Program in Women’s Oncology, Women & Infants Hospital of Rhode Island and Care New England Health System, division director, Gynecologic Oncology, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, discusses the 7-year follow up data of maintenance olaparib (Lynparza) in advanced ovarian cancer.

The phase 3 SOLO-1 trial (NCT01844986) examines maintenance olaparib monotherapy vs placebo in patients with BRCA-mutated ovarian cancer following first-line chemotherapy.

In this descriptive analysis, investigators analyzed the data with a very low alpha spend which is why the overall survival (OS) results were clinically meaningful, but not statistically significant, DiSilvestro says. The median OS in the maintenance olaparib arm has yet to be reached, and the median overall survival in the placebo arm is 75 months, DiSilvestro explains. This yields a hazard ratio of 0.55 or a 45% reduction in the risk of death for patients 7 years after their diagnosis, DiSilvestro adds.

This means, 67% of women in the olaparib arm were alive 7 years after their diagnosis vs 47% in the placebo arm, DiSilvestro concludes.